top of page
1/2
Pioneering Novel
Life-Saving Medicines
for Cardiomyopathies
Our Mission
At Nuevocor, our mission is to transform the treatment of untreatable cardiomyopathies by embracing a mechanobiology-centered approach.
These devastating conditions pose a significant global healthcare challenge, affecting individuals at a relatively young age and can rapidly lead to heart failure. Presently, the only recourse for these patients is a costly and often elusive cardiac transplant.
To address this challenge, we are building global collaborations with leading experts and institutions, accelerating the development of innovative solutions that offer these patients viable alternatives and improved outcomes.
About Us
With global operations across the United States, Europe and Singapore, Nuevocor focuses on treating heart conditions known as cardiomyopathies by addressing their underlying mechanical defects.
Nuevocor’s lead program, NVC-001, is a novel genetic medicine that treats patients suffering from LMNA-related dilated cardiomyopathy, an aggressive, rare disease with no available targeted treatments.
News
6 May 2025
Nuevocor Closes US$45 Million Series B Financing for Clinical Development of Lead Asset
​SINGAPORE and PHILADELPHIA, May 6, 2025 /PRNewswire/ -- Nuevocor, a Singapore-headquartered IND-stage biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced the successful completion of US$45 million Series B financing.
24 January 2025
Nuevocor Welcomes Andreas Wallnöfer as Chairman of the Board of Directors
SINGAPORE and PHILADELPHIA, Jan. 24, 2025 /PRNewswire/ -- Nuevocor, an IND-stage biotechnology company dedicated to developing functional cures to treat cardiomyopathies with aberrant mechanobiology, today announces the appointment of Dr. Andreas Wallnöfer as Chairman of Nuevocor's Board of Directors.
bottom of page